Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07520045) titled 'Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab' on April 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Osijek University Hospital
Condition:
Diabetic Retinopathy (DR)
Diabetic Macular Edema (DME)
Intervention:
Drug: Faricimab
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: March 12, 2026
Target Sample Size: 100
Countries of Recruitment:
Croatia
To know more, visit https://clinicaltrials.gov/study/NCT07...